Waskin H, Hardy WD, McClain N, Fall H; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 227 (abstract no. Th.B.422).
Duke Medical Center, Durham, North Carolina, USA
OBJECTIVE: To prospectively monitor post-PCP patients for glucose dysfunction and to identify the risk of dysglycemia in patients who subsequently receive aerosolized pentamidine (AP) for secondary prophylaxis. METHOD: Glucose tolerance testing (GTT) (oral 75 gm load) was performed on 35 patients who had recently recovered from first episode PCP. Followup GTTs were performed at 6 and 12 months. The diagnosis of diabetes was based on standard GTT criteria (glucose greater than or equal to 200 mg/dl at 1 and 2 hr). RESULTS: Four of 35 (11.4%) patients met the criteria for diabetes on initial GTT testing. All 4 had received IV pentamidine for acute treatment of PCP; the likelihood of diabetes in persons having received IV pentamidine for acute PCP treatment was 22.2% (4/18). No patient who received only sulfa drugs or dapsone for acute PCP treatment had an abnormal GTT (p=0.06; Fishers exact test). 17 patients who subsequently received AP have undergone followup GTT testing; only 1 (5.9%) had GTT evidence of diabetes. This patient received IV pentamidine for acute PCP 6 months earlier. None of the patients exposed de novo to AP had an abnormal GTT. SUMMARY: Among HIV+ persons, diabetes following systemic pentamidine treatment is common (22.2%); however, prophylactic aerosolized pentamidine is much less likely to cause diabetes (5.9%). Further followup of these patients is in progress.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Dapsone
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- HIV Infections
- HIV Seropositivity
- Humans
- Pentamidine
- Pneumonia, Pneumocystis
Other ID:
UI: 102181997
From Meeting Abstracts